Additionally, for patients with estrogen receptor-positive (ER+) or progesterone receptor-positive (PR+) BC who are refractory to endocrine therapy, or patients who have triple negative BC, targeted therapeutic options remain quite limited. This evidence concerns the gene PGR and breast cancer.